# Trading Cycle Report - 2026-06-14

**Environment**: staging
**Cycle covered**: runs 717-720
**Cycle triggered**: manual at 2026-06-14 07:24:55 UTC (post-deploy baseline-behavior check)
**Cycle duration**: ~1m 11s (07:24:55 → 07:26:06)
**Overall result**: 4/4 completed, 3 trades executed, 1 HOLD, 0 failed

---

## Cycle Summary — 2026-06-14 07:24 UTC

| Agent  | Style              | Decision | Symbol | Qty | Price    | Total      | Candidates              |
|--------|--------------------|----------|--------|-----|----------|------------|-------------------------|
| George | Contrarian Macro   | BUY      | FCX    | 82  | $68.41   | $5,609.62  | CCJ, LNG, SCCO, SQM     |
| Warren | Value Investor     | HOLD     | —      | —   | —        | —          | CSCO, KO, PG, TXN       |
| Ray    | Risk Parity        | BUY      | KO     | 77  | $82.62   | $6,361.74  | JNJ, KO, PG             |
| Cathie | Growth Innovation  | SELL     | ISRG   | 13  | $411.06  | $5,343.78  | AI, PATH, CRSP, COIN    |

---

## Portfolio Snapshots (Latest)

| Agent  | Cash       | Holdings Value | Total Value  | Total P&L     | Return %   |
|--------|------------|----------------|--------------|---------------|------------|
| Warren | $36,088.11 | $73,587.31     | $109,675.42  | +$9,675.42    | +9.68%     |
| George | $23,369.76 | $78,597.37     | $101,967.13  | +$1,967.13    | +1.97%     |
| Ray    | $36,255.31 | $62,033.29     | $98,288.60   | -$1,711.40    | -1.71%     |
| Cathie | $22,424.38 | $103,004.31    | $125,428.69  | +$25,428.69   | +25.43%    |

**Combined portfolio**: $435,359.84 · **Combined P&L**: +$35,359.84 (+8.84% blended return).

---

## Guardrail Columns Sanity-Check (V2/V3 Audit)

Per-phase guardrail-column population across all 8 phase rows (4 research + 4 decision) for runs 717-720:

| Run | Phase    | guardrail_attempts | guardrail_outcome | guardrail_issues | guardrail_failed_output |
|-----|----------|-------------------:|-------------------|------------------|-------------------------|
| 717 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 717 | decision | 1                  | `first_try`       | NULL             | NULL                    |
| 718 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 718 | decision | 1                  | `first_try`       | NULL             | NULL                    |
| 719 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 719 | decision | 1                  | `first_try`       | NULL             | NULL                    |
| 720 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 720 | decision | 1                  | `first_try`       | NULL             | NULL                    |

**Verdict**: PASS — 8/8 phase rows clean. All `guardrail_attempts=1`, all `guardrail_outcome='first_try'`, all `guardrail_issues=NULL`, all `guardrail_failed_output=NULL`. The V2/V3 persistence path through Python → Java DTO → JPA → Postgres remains intact after today's redeploy. The HOLD path (run 718) writes the guardrail columns the same way the BUY/SELL paths do — no behavioral divergence.

---

## Current Holdings

### Warren (10 positions)
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| ADP    | 29  | $218.35   | $6,332.15   |
| BRK.B  | 36  | $479.95   | $17,278.22  |
| JNJ    | 26  | $230.69   | $5,997.94   |
| LMT    | 12  | $520.07   | $6,240.84   |
| MCD    | 19  | $301.84   | $5,734.96   |
| MRK    | 63  | $111.92   | $7,050.96   |
| ORCL   | 26  | $232.28   | $6,039.28   |
| PEP    | 44  | $144.27   | $6,347.88   |
| V      | 20  | $322.52   | $6,450.40   |
| WMT    | 51  | $121.04   | $6,173.04   |

### George (10 positions)
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| ALB    | 48  | $159.06   | $7,634.88   |
| CF     | 58  | $114.40   | $6,635.20   |
| FCX    | 179 | $69.62    | $12,461.93  |
| FNV    | 30  | $225.38   | $6,761.40   |
| LMT    | 15  | $530.13   | $7,951.95   |
| MP     | 127 | $57.57    | $7,311.39   |
| NEM    | 76  | $97.59    | $7,416.84   |
| NTR    | 122 | $65.03    | $7,933.66   |
| WFC    | 86  | $83.73    | $7,200.78   |
| XOM    | 48  | $147.90   | $7,099.20   |

### Ray (10 positions)
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| ADP    | 28  | $218.35   | $6,113.80   |
| DUK    | 51  | $124.97   | $6,373.47   |
| KO     | 77  | $82.62    | $6,361.74   |
| MDT    | 72  | $83.32    | $5,999.04   |
| O      | 106 | $59.91    | $6,350.46   |
| TRV    | 20  | $301.53   | $6,030.60   |
| VZ     | 132 | $47.97    | $6,332.04   |
| WM     | 25  | $228.77   | $5,719.25   |
| WMT    | 52  | $120.72   | $6,277.44   |
| XOM    | 43  | $147.53   | $6,343.79   |

### Cathie (9 positions)
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| ARM    | 31  | $213.27   | $6,611.37   |
| ASML   | 7   | $1,658.87 | $11,612.08  |
| CRWD   | 10  | $731.00   | $7,310.00   |
| DDOG   | 36  | $227.34   | $8,184.24   |
| GOOGL  | 33  | $318.28   | $10,503.24  |
| META   | 9   | $566.98   | $5,102.82   |
| MSFT   | 11  | $424.62   | $4,670.82   |
| NVDA   | 135 | $183.91   | $24,827.85  |
| PLTR   | 110 | $130.60   | $14,365.73  |

---

## Detailed Run Data

### Run 717: George (Contrarian Macro)

**Started**: 2026-06-14 07:24:55 UTC | **Completed**: 2026-06-14 07:26:03 UTC
**Status**: COMPLETED

#### Research Phase (42,407 ms)
**Candidates**: CCJ, LNG, SCCO, SQM

**Tool Calls** (9):
1. `brave_web_search(query="uranium market tightness 2026 CCJ Reuters US uranium supply 2026", count=3)`
2. `brave_web_search(query="Cheniere LNG demand 2026 exports Europe 2026 Reuters Cheniere outlook 2026 LNG market tightness", count=3)`
3. `brave_web_search(query="copper supply tightness 2026 Southern Copper outlook 2026 Reuters copper deficit 2026", count=3)`
4. `brave_web_search(query="Southern Copper SCCO 2026 outlook Reuters Southern Copper 2026 profit guidance 2026 Reuters SCCO", count=3)`
5. `brave_web_search(query="SQM lithium 2026 outlook lithium market 2026 demand supply SQM Reuters 2026", count=3)`
6. `lookup_price_tool(symbol="CCJ")`
7. `lookup_price_tool(symbol="LNG")`
8. `lookup_price_tool(symbol="SCCO")`
9. `lookup_price_tool(symbol="SQM")`

**Research Notes**:
> Macro-driven candidates selected to exploit supply-driven commodity dislocations and energy-export arbitrage while avoiding overlap with core holdings. Cameco (CCJ) is a contrarian play on a tightening uranium market as utilities rush to contract fuel after multi-year underinvestment — asymmetric upside if term contracting accelerates. Cheniere Energy (LNG) captures structurally higher LNG demand and tight seasonal European/Asian markets; US export capacity and global gas shortages create durable cashflow optionality. Southern Copper (SCCO) is a leveraged play on an emerging copper structural deficit from electrification and underinvestment in new mines — a direct complement to existing base-metals exposure but with different jurisdictional leverage. SQM (SQM) gives diversified, lower-cost lithium exposure to an accelerating battery demand cycle and recent signs of a lithium price floor — a contrarian buy amid cyclical sentiment weakness.
>
> Each name fits George's contrarian macro style: concentrated exposure to paradigm shifts (nuclear fuel cycle, global gas markets, electrification metals, battery raw materials), clear supply/demand asymmetries, and idiosyncratic catalysts (utility contracting, export growth, mine production guidance, lithium pricing dynamics) that can re-rate sentiment quickly.

**Web Sources**:
- [Is the US uranium market about to go nuclear in 2026? | Reuters](https://www.reuters.com/markets/commodities/is-us-uranium-market-about-go-nuclear-2026-2026-01-14/)
- [Uranium Price Update: Q1 2026 in Review | INN](https://investingnews.com/uranium-forecast/)
- [Cheniere reports Q1 loss but raises 2026 outlook on higher LNG output, margins | Reuters](https://www.reuters.com/business/energy/cheniere-energy-posts-first-quarter-loss-2026-05-07/)
- [Global natural gas demand growth set to accelerate in 2026 as more LNG supply comes to market - IEA](https://www.iea.org/news/global-natural-gas-demand-growth-set-to-accelerate-in-2026-as-more-lng-supply-comes-to-market)
- [Copper's tight supply and tariff risks set for a volatile 2026 - MINING.COM](https://www.mining.com/coppers-tight-supply-and-tariff-risks-set-for-a-volatile-2026/)
- [SQM rises as Scotiabank says lithium demand, low costs support outlook | Reuters](https://www.reuters.com/world/americas/sqm-rises-scotiabank-says-lithium-demand-low-costs-support-outlook-2026-06-09/)

**Portfolio Context**: Balance $28,979.38, 10 positions (LMT, XOM, FNV, NTR, ALB, NEM, CF, MP, WFC, FCX).

#### Decision Phase (21,908 ms)
**Decision**: BUY FCX x82

**Reasoning**:
- **Research**: Market Analyst candidates considered: CCJ ($100.96) — Reuters: US uranium market tightening; LNG ($241.28) — Reuters: Cheniere raised 2026 outlook on higher LNG output; SCCO ($189.79; TTM P/E ≈28.7) — Mining.com/S&P Global: copper supply tightness; SQM ($84.12) — Reuters/Scotiabank: lithium demand/price floor. I chose to add to FCX rather than open SCCO/SQM/CCJ/LNG because (1) FCX is the liquid, already-held proxy for the copper/structural deficit thesis (avoids selling to free a slot), (2) SCCO trades at a higher producer multiple (~28.7 TTM P/E) and would add a new concentrated position, and (3) ALB is already in the book for lithium exposure, while uranium/energy would require repositioning — adding FCX preserves conviction exposure with lower execution/timing risk.
- **Portfolio**: Cash $28,979.38; positions 10/10. Current FCX: 97 shares @ $65.81 avg. Buying 82 shares x $70.64 = $5,792.48 fits the $5,795.88 per-trade cap and stays within available cash; this increases copper exposure without exceeding the 10-position limit or creating a new holding slot.
- **Historical**: Trade history shows an accumulating pattern in FCX (6 trades over 90 days: multiple buys at $61–$70 and tactical sells), current position 97 shares with avg cost $65.81 — demonstrates familiarity and timing/size discipline in this sector.

**Rationale**: Add to existing Freeport (FCX) to express the Market Analyst's copper/cyclical thesis via a liquid, already-held miner — copper structural deficit offers asymmetric upside while avoiding opening a new position slot.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="FCX")`

#### Execution
**Trade**: BUY 82 shares FCX @ $68.41 = $5,609.62 (trade_id 577). Note: decision-time quoted price was $70.64 but execution filled at $68.41 (market move between decision and execution).

---

### Run 718: Warren (Value Investor)

**Started**: 2026-06-14 07:24:55 UTC | **Completed**: 2026-06-14 07:26:03 UTC
**Status**: COMPLETED

#### Research Phase (43,914 ms)
**Candidates**: CSCO, KO, PG, TXN

**Tool Calls** (7):
1. `brave_web_search(query="CSCO TXN KO PG ROE P/E free cash flow 2026 company analysis undervalued Cisco Texas Instruments Coca-Cola Procter & Gamble ROE P/E 2026", count=10)`
2. `brave_web_search(query="KO PG TXN ROE P/E free cash flow 2026 Coca-Cola Procter & Gamble Texas Instruments undervalued ROE P/E 2026 analysis", count=10)`
3. `brave_web_search(query="Texas Instruments TXN ROE P/E free cash flow 2026 valuation undervalued TXN ROE 2026 analysis", count=10)`
4. `lookup_price_tool(symbol="CSCO")`
5. `lookup_price_tool(symbol="KO")`
6. `lookup_price_tool(symbol="PG")`
7. `lookup_price_tool(symbol="TXN")`

**Research Notes**:
> I screened for high-quality, cash-generative companies with durable moats, multi-year earnings consistency, strong ROE and conservative balance sheets. Four candidates met Warren-style value criteria: Cisco (CSCO) — large networking/software moat, ~25% ROE, strong free cash flow and reasonable valuation vs. peers; Coca-Cola (KO) — dominant consumer brand with multi-year cash flow stability and elevated ROE; Procter & Gamble (PG) — broad consumer-staples moat, consistent earnings and shareholder-friendly capital allocation; Texas Instruments (TXN) — analog semiconductor leader with >30% ROE, very strong FCF and disciplined capital returns. Each ticker trades on US exchanges and I verified current market prices for portfolio compatibility.

**Web Sources**:
- [Cisco Systems (CSCO) Statistics & Valuation](https://stockanalysis.com/stocks/csco/statistics/)
- [Cisco Systems, Inc. (CSCO) Stock Price - Yahoo Finance](https://finance.yahoo.com/quote/CSCO/)
- [Is Cisco Systems (CSCO) Pricing Reflect Its Cash Flow And Earnings Potential? - Simply Wall St](https://simplywall.st/stocks/us/tech/nasdaq-csco/cisco-systems/news/is-cisco-systems-csco-pricing-reflect-its-cash-flow-and-earn/amp)
- [The Coca-Cola Company (KO) Statistics & Valuation](https://stockanalysis.com/stocks/ko/statistics/)
- [The Coca-Cola Company (KO) Stock Price - Yahoo Finance](https://finance.yahoo.com/quote/KO/)
- [Coca-Cola Stock Is Up 11% in 2026: Here's What Could Drive KO Next | TIKR.com](https://www.tikr.com/blog/coca-cola-stock-is-up-11-in-2026-heres-what-could-drive-ko-next)
- [The Procter & Gamble Company (PG) Valuation Measures & Financial Statistics - Yahoo Finance](https://finance.yahoo.com/quote/PG/key-statistics/)
- [Texas Instruments (TXN) Statistics & Valuation](https://stockanalysis.com/stocks/txn/statistics/)
- [Texas Instruments 2025 Annual Report / Notice of 2026 Annual Meeting (Investor site)](https://investor.ti.com/static-files/fc9d9346-cf77-40db-902a-e9961e9c5736)
- [Texas Instruments: What's Next After Its Free Cash Flow Nearly Doubled Last Year? - TIKR](https://www.tikr.com/blog/texas-instruments-whats-next-after-its-free-cash-flow-nearly-doubled-last-year)

**Portfolio Context**: Balance $36,088.11, 10 positions (BRK.B, WMT, JNJ, PEP, MCD, ORCL, ADP, MRK, LMT, V).

#### Decision Phase (20,622 ms)
**Decision**: HOLD

**Reasoning**:
- **Research**: Market Analyst candidates reviewed: CSCO (price $121.10; analyst notes trailing/forward P/E in the high-teens to high-20s — StockAnalysis/Yahoo Finance), KO (price $82.62; trailing P/E ≈ mid-20s and ~2.7–2.8% yield), PG (price $149.61; trailing P/E ≈21), TXN (price $301.12; ROE >30% but trailing/forward P/E typically mid-to-high-30s per StockAnalysis/TI investor filings). I decline to buy because: TXN appears richly valued relative to intrinsic-value criteria; KO/PG materially overlap staples exposure (we already hold PEP/MCD) without a clear valuation edge; CSCO has shown recent account churn and execution variability.
- **Portfolio**: Cash $36,088.11; positions 10/10 (BRK.B, WMT, JNJ, PEP, MCD, ORCL, ADP, MRK, LMT, V). Max per-position cap $5,413.22 and position limit prevents opening a new slot without a prior sell; none of the four candidates are current holdings, so any buy would require a separate sell cycle.
- **Historical**: CSCO trade history shows repeated buys/sells in the past 90 days (multiple round-trips with an overall accumulating pattern), indicating execution/churn risk rather than stable buy conviction.

**Rationale**: No trade — account is fully allocated (10/10) and none of the Market Analyst candidates offer a clear margin-of-safety versus incumbents or justify selling a current high-conviction holding this cycle.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="CSCO")`

#### Execution
No execution phase row written — HOLD path short-circuits at the execution boundary. Consistent with prior HOLD behavior.

---

### Run 719: Ray (Risk Parity)

**Started**: 2026-06-14 07:24:55 UTC | **Completed**: 2026-06-14 07:25:57 UTC
**Status**: COMPLETED

#### Research Phase (39,351 ms)
**Candidates**: JNJ, KO, PG

**Tool Calls** (10):
1. `brave_web_search(query="Johnson & Johnson JNJ dividend yield beta 2026 Yahoo Finance dividend aristocrat site:yahoo.com", count=5)`
2. `brave_web_search(query="Johnson & Johnson investor relations dividends dividend history JNJ investor.jnj.com dividend \"Johnson & Johnson\" dividends 2026", count=5)`
3. `brave_web_search(query="Coca-Cola KO dividend yield beta 2026 Yahoo Finance dividend aristocrat KO beta dividend yield 2026 site:yahoo.com", count=5)`
4. `brave_web_search(query="Coca-Cola investor relations dividend history KO dividend 2026 \"investor coca-cola\" dividend history", count=5)`
5. `brave_web_search(query="Coca-Cola investor relations dividend history KO investor relations dividend 2026 site:coca-colacompany.com", count=10)`
6. `brave_web_search(query="Procter & Gamble PG dividend yield beta 2026 Yahoo Finance dividend aristocrat PG investor relations dividend 2026 site:pg.com", count=10)`
7. `brave_web_search(query="Procter & Gamble PG stock quote Yahoo Finance beta dividend yield PG Yahoo Finance quote", count=5)`
8. `lookup_price_tool(symbol="JNJ")`
9. `lookup_price_tool(symbol="KO")`
10. `lookup_price_tool(symbol="PG")`

**Research Notes**:
> I selected three defensive, low-beta dividend aristocrats that fit a risk-parity, all-weather sleeve: JNJ (healthcare), KO (beverages/consumer staples), and PG (consumer staples). Each has a long dividend-growth track record, strong balance sheets, and lower market betas—helping reduce portfolio volatility and provide steady income across recessionary and inflationary regimes. These names add sectoral balance (healthcare + staples) to complement the portfolio's existing utilities, energy, REIT and industrial exposures while keeping downside resilience and low correlation in focus.
>
> These candidates were chosen for high conviction given repeated prior consideration in recent runs, their defensive cash flows, and their roles across economic quadrants: JNJ (healthcare — defensive in recession/deflation and less cyclical), KO (staples — defensive consumption, low beta), PG (broad consumer staples — pricing power and durable cash generation). All trade on US exchanges and present straightforward diversification benefits for a near-capacity, risk-parity portfolio.

**Web Sources**:
- [Johnson & Johnson (JNJ) Stock Price, News, Quote & History - Yahoo Finance](https://finance.yahoo.com/quote/JNJ/)
- [Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%](https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-Announces-64th-Consecutive-Year-of-Dividend-Increase-Raises-Quarterly-Dividend-by-3-1/default.aspx)
- [The Coca-Cola Company - Dividends - Coca-Cola Investor Relations](https://investors.coca-colacompany.com/stock-info/dividends)
- [The Coca-Cola Company (KO) Stock Price, News, Quote & History - Yahoo Finance](https://finance.yahoo.com/quote/KO/)
- [P&G Declares Quarterly Dividend, January 2026](https://us.pg.com/newsroom/news-releases/PG-Declares-Quarterly-Dividend-January-2026/)
- [The Procter & Gamble Company (PG) Stock Price, News, Quote & History - Yahoo Finance](https://finance.yahoo.com/quote/PG/)

**Portfolio Context**: Balance $42,617.05, 9 positions (WM, VZ, TRV, XOM, DUK, O, WMT, MDT, ADP).

#### Decision Phase (19,124 ms)
**Decision**: BUY KO x77

**Reasoning**:
- **Research**: Market Analyst candidates considered: JNJ (healthcare; price $240.87; trailing P/E ≈22; dividend growth), KO (beverages; price $82.62; trailing P/E mid-20s; yield ≈2.7–3.0%), PG (consumer staples; price $149.61; trailing P/E ≈20–21; broad household franchises). I chose KO because, versus JNJ (which increases healthcare overlap with existing MDT) and PG (which overlaps more with retail/household exposure like WMT), KO's beverage franchise provides a more orthogonal defensive cash flow stream and lower marginal correlation to the portfolio's current sectors while meeting valuation/yield objectives.
- **Portfolio**: Cash $42,617.05; positions 9/10. Buying 77 KO shares at $82.62 = $6,361.74 (<= cash and <= max_position_value $6,392.56) fills the final slot and modestly increases low-volatility income exposure without breaching the 15% per-position limit.
- **Historical**: Recent trading history (last 90 days) shows mixed activity in KO with 3 buys and 3 sells (e.g., bought 80 @ $79.01 on 2026-05-31 then sold 80 @ $79.01 on 2026-06-01; multiple earlier buys/sells), indicating prior tactical re-entries; overall pattern = churn but consistent interest in KO as a defensive staple.

**Rationale**: KO adds low-beta, defensive beverage exposure with steady dividends and lower marginal correlation to the current healthcare/industrial sleeve, improving risk-adjusted diversification while fitting the per-position cap.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="KO")`

#### Execution
**Trade**: BUY 77 shares KO @ $82.62 = $6,361.74 (trade_id 576)

---

### Run 720: Cathie (Growth Innovation)

**Started**: 2026-06-14 07:24:55 UTC | **Completed**: 2026-06-14 07:26:06 UTC
**Status**: COMPLETED

#### Research Phase (50,317 ms)
**Candidates**: AI, PATH, CRSP, COIN

**Tool Calls** (8):
1. `brave_web_search(query="C3.ai 2026 revenue growth 2026 AI enterprise news June 2026 C3.ai earnings 2026", count=5)`
2. `brave_web_search(query="UiPath 2026 revenue growth Q1 2026 RPA automation earnings May 2026 UiPath strategic initiatives 2026 news", count=5)`
3. `brave_web_search(query="CRISPR Therapeutics 2026 clinical progress revenue 2026 gene editing CRSP news June 2026 clinical trial updates", count=5)`
4. `brave_web_search(query="Coinbase Q1 2026 revenue growth Coinbase 2026 crypto exchange regulatory outlook June 2026 COIN news", count=5)`
5. `lookup_price_tool(symbol="AI")`
6. `lookup_price_tool(symbol="PATH")`
7. `lookup_price_tool(symbol="CRSP")`
8. `lookup_price_tool(symbol="COIN")`

**Research Notes**:
> I screened for disruptive-growth names that expand Cathie-style exposure beyond current holdings (enterprise AI/automation, genomics gene editing, and crypto-fintech). The four candidates—C3.ai (AI), UiPath (PATH), CRISPR Therapeutics (CRSP) and Coinbase (COIN)—are leaders or first-movers in their niches: C3.ai is a pure-play enterprise AI software vendor undergoing restructuring to refocus on topline growth; UiPath is the RPA/agentic automation leader commercializing higher-value AI automation; CRISPR Therapeutics is a gene-editing platform with commercial and clinical milestones in 2026; Coinbase is the dominant U.S. crypto exchange expanding subscription/services and derivatives revenue. Each name offers asymmetric upside tied to platform adoption, product-led growth, or regulatory normalization in crypto.
>
> Given the portfolio is at capacity, these candidates were chosen to complement existing tech-heavy positions (NVDA, MSFT, ARM, META, PLTR) by adding underweight but high-leverage exposure: AI application software at a value entry (AI), automation scale and ARR expansion (PATH), differentiated genomics/gene-editing upside (CRSP) versus surgical robotics exposure (ISRG), and regulated crypto/fintech infrastructure exposure (COIN) versus broad ad/compute/AI exposure already held.

**Web Sources**:
- [C3 AI Announces Preliminary Fourth Quarter and Full Fiscal Year 2026 Results](https://ir.c3.ai/news-releases/news-release-details/c3-ai-announces-preliminary-fourth-quarter-and-full-fiscal-year-2026-results/)
- [C3.ai (AI) Reports Q4 Fiscal 2026 Earnings Amid Restructuring Efforts](https://www.gurufocus.com/news/8900044/c3ai-ai-reports-q4-fiscal-2026-earnings-amid-restructuring-efforts)
- [UiPath Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results](https://ir.uipath.com/news/detail/431/uipath-reports-fourth-quarter-and-full-year-fiscal-2026-financial-results)
- [Earnings call transcript: UiPath Q1 2026 beats expectations, shares jump](https://www.investing.com/news/transcripts/earnings-call-transcript-uipath-q1-2026-beats-expectations-shares-jump-93CH-4071636)
- [CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones](https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-highlights-strategic-priorities-and-anticipated-2026-milestones)
- [CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones - BioSpace](https://www.biospace.com/press-releases/crispr-therapeutics-highlights-strategic-priorities-and-anticipated-2026-milestones/)
- [Coinbase Q1 Financial Results Show Resilient Financial Performance](https://investor.coinbase.com/news/news-details/2026/Coinbase-Q1-Financial-Results-Show-Resilient-Financial-Performance-Driven-by-New-All-Time-High-Crypto-Trading-Volume-Market-Share/default.aspx)
- [Coinbase (COIN) earnings Q1 2026 - CNBC](https://www.cnbc.com/2026/05/07/coinbase-coin-earnings-q1-2026.html)

**Portfolio Context**: Balance $17,080.60, 10 positions (NVDA, DDOG, GOOGL, ASML, PLTR, CRWD, ISRG, META, ARM, MSFT).

#### Decision Phase (16,893 ms)
**Decision**: SELL ISRG x13

**Reasoning**:
- **Research**: Market Analyst candidates: C3.ai (AI) — pure-play enterprise AI, current price $10.90, but undergoing restructuring/execution risk; UiPath (PATH) — enterprise RPA/agentic automation, current price $10.55, software multiple ~mid-20s (valuation attractive but overlaps MSFT/GOOGL exposure); CRISPR Therapeutics (CRSP) — gene-editing platform, current price $49.80, CASGEVY early commercial revenue (high upside but classic biotech binary/regulatory risk); Coinbase (COIN) — regulated crypto exchange, current price $159.78 with elevated forward valuation (analyst-cited forward P/E ≈53.9) and regulatory/volume cyclicality. I sell ISRG because CRSP offers differentiated genomics optionality versus surgical robotics, PATH overlaps existing enterprise software exposure, COIN carries high valuation/cyclicality, and C3.ai faces restructuring uncertainty — selling ISRG creates the needed capacity to add one of these higher-leverage innovation candidates in the next cycle.
- **Portfolio**: Cash $17,080.60; positions 10/10. Current holdings include NVDA, DDOG, GOOGL, ASML, PLTR, CRWD, ISRG (13 sh), META, ARM, MSFT. Selling 13 ISRG shares frees one slot and increases cash to redeploy into a higher-conviction disruptive idea in a future cycle while keeping core AI/compute positions intact.
- **Historical**: Recent trade history (last 90 days) shows active trading in ISRG (8 trades: 4 buys, 4 sells) with a mixed pattern; current position 13 shares, avg cost ≈$437.77, with recent execution prices in the ~$422–471 range — indicating volatility and intra-cycle trimming activity.

**Rationale**: Sell full ISRG position to free a 10-position slot for higher asymmetric innovation exposure (gene-editing or regulated crypto) while reducing exposure to a narrower surgical-robotics franchise.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="ISRG")`

#### Execution
**Trade**: SELL 13 shares ISRG @ $411.06 = $5,343.78 (trade_id 578)

---

## Aggregate Statistics — Cycle 717-720

| Metric                                | Value           |
|---------------------------------------|-----------------|
| Total Runs                            | 4               |
| Successful                            | 4 (100%)        |
| Failed                                | 0               |
| Total Trades                          | 3 (2 BUY, 1 SELL) |
| HOLD Decisions                        | 1 (Warren)      |
| Total Capital Deployed (gross)        | $17,315.14      |
| Avg Research Latency                  | 43,997 ms (~44s) |
| Avg Decision Latency                  | 19,637 ms (~20s) |
| Avg Research Tool Calls               | 8.5             |
| Combined Portfolio Value              | $435,359.84     |
| Combined P&L                          | +$35,359.84     |
| Blended Return                        | +8.84%          |
| Reasoning Fields Complete             | 4/4             |
| Missing Phases                        | 0 (HOLD run 718 has no execution row by design) |
| Guardrail rows populated (V2 audit)   | 8/8 (4 research + 4 decision) |
| Guardrail trips this cycle            | 0               |

---

## Comparison with Previous Report

**Previous**: `TRADING_CYCLE_REPORT_20260611.md` (cycle 05:08 UTC on 2026-06-11, runs 665-668, 4 trades + 0 HOLD)
**Current**: `TRADING_CYCLE_REPORT_20260614.md` (cycle 07:24 UTC on 2026-06-14, runs 717-720, 3 trades + 1 HOLD)

| Metric                          | Previous (665-668)     | Current (717-720)      | Status |
|---------------------------------|------------------------|------------------------|--------|
| Completion Rate                 | 4/4 (100%)             | 4/4 (100%)             | OK     |
| Failed Runs                     | 0                      | 0                      | OK     |
| Trades Executed                 | 4 (2 BUY, 2 SELL)      | 3 (2 BUY, 1 SELL)      | OK (HOLD is a valid decision) |
| HOLD Decisions                  | 0                      | 1 (Warren)             | OK     |
| Reasoning Fields Complete       | 4/4                    | 4/4                    | OK     |
| Missing Phases                  | 0                      | 0 (HOLD has no exec)   | OK     |
| Avg Research Tool Calls         | 7.25                   | 8.5                    | OK (within normal range) |
| Avg Research Latency            | ~45s                   | ~44s                   | OK     |
| Avg Decision Latency            | ~25s                   | ~20s                   | OK (-5s, improvement) |
| Combined Portfolio Value        | $428,189.51            | $435,359.84            | +$7,170.33 (market-dependent) |
| Combined P&L                    | +$28,189.51            | +$35,359.84            | +$7,170.33 (market-dependent) |
| Blended Return                  | +7.05%                 | +8.84%                 | +1.79pp (market-dependent) |
| Guardrail rows populated        | 8/8                    | 8/8                    | OK     |
| Guardrail trips                 | 0                      | 0                      | OK     |
| V2/V3 columns populated correctly | Yes                  | Yes                    | OK     |

### Regressions Found
**None.** All system-level checks passed. Warren's HOLD is a legitimate first-class decision path (10/10 positions, no candidate clears the margin-of-safety bar) and not a regression — execution_phases correctly contains no row for run 718, matching the documented HOLD short-circuit.

### V2/V3 Guardrail Columns — Populated Correctly?
**Yes.** All 8 phase rows (4 research + 4 decision) for runs 717-720 carry `attempts=1`, `outcome='first_try'`, `issues=NULL`, `failed_output=NULL`. The HOLD path (run 718) writes guardrail columns identically to BUY/SELL paths. The persistence wiring through Python → Java DTO → JPA → Postgres remains intact.

### Backend DTO — `guardrailFailedOutput` Field Exposed?
**Yes.** `curl -s https://staging.agentic-trading.vkontech.com/api/runs/717` returns the field on both `research` and `decision` objects:

```
research.guardrailFailedOutput = null
decision.guardrailFailedOutput = null
```

The field is present in the response shape (key exists) and serialized as `null` for these `first_try` runs — exactly the contract the frontend's `GuardrailBadge` popover expects when rendering a clean run. Previously the DTO omitted this field; today's backend redeploy includes it.

### Backend Log Errors Since Latest Deploy
Searched `kubectl logs deploy/backend -n agentic-trading-staging --since=1h | grep -iE 'error|exception'`. 19 matches total — **all** are `WARN` entries from `com.trading.exception.GlobalExceptionHandler` with the single message `"Access denied: Access Denied"`, sourced from unauthenticated UI/API calls landing on the GlobalExceptionHandler's 403 path. No `ERROR`-level entries, no stack traces, no DTO/JPA/serialization exceptions, no cycle-path failures.

### Style Distribution
- George (Contrarian Macro) — BUY FCX (add to existing copper position, contrarian commodity thesis)
- Warren (Value Investor) — HOLD (10/10 full, no margin-of-safety candidate)
- Ray (Risk Parity) — BUY KO (low-beta beverage staple, fill 10th slot)
- Cathie (Growth Innovation) — SELL ISRG (free slot for next-cycle innovation rotation)

---

## Closing Note

All four staging pods are healthy: `kubectl get pods -n agentic-trading-staging` shows `agents-785b88f7c4-4wfrs` Running 1/1 (~3m old, consistent with the just-completed agents redeploy back to baseline `_PLACEHOLDER_DOMAINS`), `backend-5b7d46cf5d-q7zhn` Running 1/1 (~14h, carries the `guardrailFailedOutput` DTO addition verified above), `frontend-86849fcb8c-hmm7x` Running 1/1 (~71m, ships the `GuardrailBadge` popover that replaces the old hover-tooltip), and `postgres-0` Running 1/1 (57d, unchanged). No restarts on any pod. The frontend deploy completed successfully — the popover behavior change is whatever the served build contains, no behavioral verification performed here. Grafana V4 panels and V5 alert rule remain loaded in the `monitoring` namespace from prior deploys (not re-tested in this cycle, no events to surface anyway since 0 guardrail trips occurred).
